Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 673 | Ordered by Date (descending)
1 2 3 4 5 6 7  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Anocca–SEVERAL: investment, 202107 financing round Series B SEK400m ($47m) led by Danske Bank 2021-07-22
Fertin Pharma–Philip Morris: investment, 202107– acquisition DKK5.1b ($820m) from EQT + Bagger-Sørensen ANNOUNCED 2021-07-01
Discover Echo–Cellink: investment, 202106– acquisition $110m with $98m in cash + $12m in new Series B shares ANNOUNCED 2021-06-26
Owler–Meltwater: investment, 202106– acquisition $24.5m with $18.9m in cash + $5.6m in equity ANNOUNCED 2021-06-18
Aldevron–Danaher: investment, 202106– acquisition $9.6b in cash by Danaher ANNOUNCED 2021-06-17
Kahr-Medical–Flerie Invest: investment, 202106 financing round totalling $46.5m incl existing + co-investor Flerie Invest AB 2021-06-16
Kahr-Medical–SEVERAL: investment, 202106 financing round $46.5m led by aMoon 2021-06-16
AstraZeneca–Proteros: small-molecule cancer drugs, 202106– collab r+d + license agreem with research funding + $62m milestones + royalties 2021-06-02
Origin.bio–EQT: investment, 202105 financing round totalling $15m incl lead investor EQT Ventures 2021-05-26
Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Sten Tamkivi 2021-05-26
Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Taavet Hinrikus 2021-05-26
Origin.bio–SEVERAL: investment, 202105 financing round $15m led by EQT Ventures 2021-05-26
Numab–Novo Group: investment, 202105 financing round Series C totalling CHF100m incl new + co-lead investor Novo Holdings 2021-05-20
Numab–SEVERAL: investment, 202105 financing round Series C CHF100m co-led by new investors Novo Holdings + HBM Partners 2021-05-20
Nanoscribe–Cellink: investment, 202105 acquisition 100% of Nanoscribe Holding for preliminary €36.9m with €24.7m cash + €12.2m in Series B shares 2021-05-19
Hummingbird Bioscience–Novo Group: investment, 202105 financing round Series C totalling $125m incl lead investor Novo Holdings 2021-05-18
Hummingbird Bioscience–SEVERAL: investment, 202105 financing round Series C $125m led by Novo Holdings 2021-05-18
AMSilk–Novo Group: investment, 202105 financing round Series C totalling €29m incl new + lead investor Novo Growth 2021-05-11
AMSilk–SEVERAL: investment, 202105 financing round Series C €29m led by Novo Growth with Cargill + ER Capital Holdings + MIG AG + Athos KG 2021-05-11
Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial 2021-05-05
Cytoki Pharma–BPCE: investment, 202105 financing round Series A totalling $45m incl co-investor Seventure Partners 2021-05-05
Cytoki Pharma–Lundbeck: investment, 202105 financing round Series A totalling $45m incl existing + lead investor Lundbeckfonden Emerge 2021-05-05
Cytoki Pharma–SEVERAL: investment, 202105 financing round Series A $45m led by existing investor Lundbeckfonden Emerge 2021-05-05
Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital 2021-05-05
Oculis–SEVERAL: investment, 202105 financing round Series C $57m co-led by new investors BVCF Management + Hyfinity Investments 2021-05-04
Adcendo–Gilde Investment: investment, 202104 financing round Series A totalling €51m incl co-investor Gilde Healthcare 2021-04-29
Adcendo–Novo Group: investment, 202104 financing round Series A totalling €51m incl co-lead investor Novo Seeds 2021-04-29
Adcendo–Odlander Fredrikson: investment, 202104 financing round Series A totalling €51m incl co-investor RA HealthCap 2021-04-29
Adcendo–Optimum Strategic Communications: public relations, 202104 service existent by Optimum 2021-04-29
Adcendo–RA Capital: investment, 202104 financing round Series A totalling €51m incl co-investor RA Capital Management 2021-04-29
Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital 2021-04-29
Adcendo–Ysios Capital: investment, 202104 financing round Series A totalling €51m incl co-lead investor Ysios Capital 2021-04-29
Exscientia–Novo Group: investment, 202104 financing round Series D totalling $225m incl existing + co-investor Novo Holdings 2021-04-27
Exscientia–SEVERAL: investment, 202104 financing round Series D $225m led by SoftBank Vision Fund 2 2021-04-27
Alligator Bioscience–MacroGenics: antibody cancer drug, 202104– collab research using Neo-X-Prime plus DART+TRIDENT technologies against two targets 2021-04-15
Mobidiag–Hologic: investment, 202104– acquisition €600m in cash ANNOUNCED 2021-04-08
Step Pharma–Hadean Ventures: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Hadean Ventures 2021-03-24
Step Pharma–SEVERAL: investment, 202103 financing round Series B €35m co-led by new investors Hadean Ventures + Sunstone Life Science Ventures 2021-03-24
Step Pharma–Sunstone Life Science: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Sunstone Life Science 2021-03-24
Aura Biosciences–SEVERAL: investment, 202103 financing round $80m led by Matrix Capital Management + Surveyor Capital 2021-03-22
Cellink–SEVERAL: credit, 202103–202603 convertible bonds SEK1.5b at 2.875%pa convertible into B Class shares at SEK598.5/share 2021-03-12
Cellink–SEVERAL: investment, 202103 capital increase SEK1.5b directed issue of new Class B Shares at SEK420/share 2021-03-12
MatTek–Cellink: investment, 202103– acquisition $68m net of cash/debt with $54.4m in cash + $13.6m in shares ANNOUNCED 2021-03-10
BioPhero–DCVC: investment, 202103 financing round Series A totalling $17m incl new + lead investor DCVC Bio 2021-03-09
BioPhero–FMC: investment, 202103 financing round Series A totalling $17m incl new + co-investor FMC Ventures 2021-03-09
BioPhero–Novo Group: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Novo Holdings 2021-03-09
BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings 2021-03-09
BioPhero–Syngenta: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Syngenta Ventures 2021-03-09
Exscientia–BlackRock: investment, 202103 financing round Series C extension totalling $40m + closing at total of $100m incl new investor BlockRock 2021-03-04
Exscientia–SEVERAL: investment, 202103 financing round Series C extension $40m + closing at total of $100m with BlockRock joining existing investors 2021-03-04
Oxular–NeoMed: investment, 202103 financing round totalling £27m incl existing + co-investor NeoMed 2021-03-01
Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion 2021-03-01
Oxular–V-Bio Ventures: investment, 202103 financing round totalling £27m incl existing + co-investor V-Bio Ventures 2021-03-01
Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc 2021-02-24
Altasciences–Novo Group: investment, 202102– acquisition of Altasciences by Novo Holdings from Audax Private Equity ANNOUNCED 2021-02-22
Almirall–MC2 Therapeutics: Wynzora Cream, 202102– license excl to commercialise Wynzora Cream for plaque psoriasis in Europe for Almirall 2021-02-17
Cognate BioServices–Charles River: investment, 202102–202103 acquisition $875m in cash by Charles River 2021-02-17
Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares 2021-02-15
EnginZyme–SEB: investment, 202102 financing round Series A extension totalling €4.6m incl new + co-investor SEB Greentech VC 2021-02-11
EnginZyme–SEVERAL: investment, 202102 financing round Series A extension €4.6m led by Industrifonden + incl SEB Greentech VC + existing shareholders 2021-02-11
EnginZyme–Sweden (govt): investment, 202102 financing round Series A extension totalling €4.6m incl new + lead investor Industrifonden 2021-02-11
Evaxion Biotech–LifeSci: public relations, 202102 supply service existent by LifeSci Advisors LLC 2021-02-10
Evaxion Biotech–SEVERAL: investment, 202102 US IPO $30m+$4.5m with 3m+450k ADSs at $10/ADS at Nasdaq Capital Market 2021-02-10
IO Biotech–Avoro Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Avoro Capital 2021-01-13
IO Biotech–Eurazeo: investment, 202101 financing round Series B totalling €127m incl new + co-investor Idinvest Partners 2021-01-13
IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments 2021-01-13
IO Biotech–Kurma: investment, 202101 financing round Series B totalling €127m incl new + co-investor Kurma Partners 2021-01-13
IO Biotech–Lundbeck: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Lundbeckfonden Emerge 2021-01-13
IO Biotech–Novo Group: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Novo Seeds 2021-01-13
IO Biotech–PFM Health Sciences: investment, 202101 financing round Series B totalling €127m incl new + co-investor PFM Health Sciences 2021-01-13
IO Biotech–RA Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor RA Capital Management 2021-01-13
IO Biotech–Samsara BioCapital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Samsare BioCapital 2021-01-13
IO Biotech–Serrado Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Serrada Capital 2021-01-13
IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments 2021-01-13
IO Biotech–Soleus Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Soleus Capital 2021-01-13
IO Biotech–Sunstone Life Science: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Sunstone Life Science 2021-01-13
IO Biotech–Vivo Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Vivo Capital 2021-01-13
BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension 2021-01-07
BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
CorWave–Novo Group: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Novo Holdings 2021-01-06
CorWave–SEVERAL: investment, 202101 financing round Series C €35m led by new investor EIC Fund 2021-01-06
Faron Pharmaceuticals–Precision Medicine Group: public relations, 202101 service existent IR by Stern IR 2021-01-04
Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime 2020-12-31
Hemab–Genmab: antibody technology, 202012 existent license to DuoBody platform to develop antibodies for bleeding disorders 2020-12-14
Hemab–Novo Group: antibody technology, 202012 existent license to IP to develop antibodies for bleeding disorders from Novo Nordisk AS 2020-12-14
Hemab–Novo Group: investment, 202012 seed investor Novo Seeds 2020-12-14
Evaxion Biotech–EU (govt): credit, 202012– EIB loan €20m under InnovFin program to advance AI-based vaccine research 2020-12-09
BioInnovation Institute–Novo Group: grant, 202012–203012 up to €470m funding over ten years to BBI from Novo Nordisk Foundation 2020-12-08
Osteolabs–MVZ Dr Krause: investment, 202012 2nd financing round totalling €1.6m incl existing investor Labor Dr Krause MVZ Kiel 2020-12-08
Osteolabs–Schleswig-Holstein (govt): investment, 202012 2nd financing round totalling €1.6m incl existing investor MGB Kiel Seed and Start-Up Fonds II 2020-12-08
Osteolabs–SEVERAL: investment, 202012 2nd financing round €1.6m from MGB Kiel + MVZ Dr Krause Kiel + SVM Hamburg 2020-12-08
Osteolabs–SVM (DE): investment, 202012 2nd financing round totalling €1.6m incl new investor SVM Verwaltungsgesellschaft mbH Hamburg 2020-12-08
Single Technologies–SEVERAL: investment, 202012 financing round €5m oversubscribed share issue with existing + new investors 2020-12-04
Enduro Genetics–BioInnovation Institute: credit, 202012 pre-seed loan €470k from BII 2020-12-02
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
SynOx Therapeutics–Odlander Fredrikson: investment, 202011 financing round Series A totalling €37m incl co-lead investor HealthCap 2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent 2020-11-18
DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED 2020-11-18
1 2 3 4 5 6 7  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top